Bernard,
Although it's OK for Trickle companies to sell to clinical diagnostics customers, those that do so exclusively are not in my definition.
Meanwhile, Waters, which originally downplayed this loss in its patent dispute with MDZ and ABI, now is revising its guidance, and by more than the 2% in revenue. From CBS MarketWatch:
>>Waters (WAT: news, chart, profile) revised its 2001 results and lowered 2002 expectations as a result of an unfavorable patent ruling involving mass spectrometry products sold in the U.S. The company said 2001 earnings were reduced to 83 cents a share from $1.23, due to a $75 million pre-tax provision for estimated costs related to the patent suit. Looking ahead, the company is now anticipating reporting earnings of 27 to 29 cents a share for the first quarter of 2002 and EPS $1.37 to $1.45 for the full year. Analysts surveyed by Multex are currently forecasting EPS of 32 cents and $1.49, respectively, on average. The company plans to "aggressively" appeal the verdict, but said the result of the litigation "has been a significant disappointment." The stock closed Friday down 10 cents at $29.10.<<
snip
Cheers, Tuck |
